Health care practitioners’ perceptions of transdermal therapeutic systems in Palestinian territories

Zaid Abdel Naser


To evaluate the scientific knowledge and attitudes of health professionals in Palestine regarding the advantages of transdermal therapeutic systems (TTSs) over conventional therapy. Data were gathered from a questionnaire that was
handed out to community pharmacists and physicians. Pharmaceutical industry decision makers were enrolled in this study. Data were analyzed using the SPSS statistical software program version 10. 79.5% of pharmacists and 74% of physicians thought that TTSs eliminate variables due to gut absorption. 78.8% of pharmacists and 65.6% of physicians were in agreement
regarding the capacity of   TSs to avoid first-pass metabolism. In this study, 83.3% of the physicians and 81.3% pharmacists
T still agree that TTSs may provide controlled release. 55.8% of pharmacists and only 26% of physicians believed that TTSs eliminate drug-plasma fluctuation. 56.8% of pharmacists and 63.5% of physicians agreed that TTSs can use drugs with low therapeutic indices. 81.3% of pharmacists and 85.4% of physicians believed that TTSs are not invasive and can be removed easily to stop drug administration. 81.3% of physicians and 89.1% of pharmacists thought that TTSs may irritate or sensitize the skin. Eighty-four percent of pharmacists and 75% of physicians recognize that TTSs should contain drugs that must be
stable and have correct physicochemical properties. The importance of   TSs is understood and appreciated by Palestinian T health personnel. Pharmaceutical industries should pay more attention to the development and production of   TSs due to T the valuable advantages of this therapeutic system.

Full Text:



Segal, Marian. Patches, Pumps and Timed Release: New Ways to Deliver

Drugs. Food and Drug Administration.

consumer/CON00112.html. Retrieved on 2007;2:24.

“FDA approves scopolamine patch to prevent peri-operative nausea”.

Food and Drug Administration. 1997;10-11.

Burris JF. The USA experience with the clonidine transdermal

therapeutic system. Clin Auton Res 1993;3:391-6.

Tanner T, Marks R. Delivering drugs by the transdermal route: review

and comment. Skin Res Technol 2008;14:249-60.

Cappelli C, Reale G, Marucci G, Clerico A. Transdermal fentanyl: A new

tool for pain therapy in pediatric oncology. Clin Ter 2008;159:257-60.

Finnin BC. Transdermal drug delivery: What to expect in the near future,

business briefing. Pharmatech 2003;192-3.

Kumar R, Philip A. Modified transdermal technologies: Breaking the barriers of drug permeation via the skin. Trop J Pharma Res 2007;6:633-44.

Langer R. Transdermal drug delivery: Past progress, current status, and

future prospects. Adv Drug Deliv Rev 2004;56:557-8.

Braun M, Cawello W, Boekens H, Horstmann R. Influence of

domperidone on pharmacokinetics, safety and tolerability of the

dopamine agonist rotigotine. Br J Clin Pharmacol 2009;67:209-15.

Hupfeld S, Gravem H. Tidsskr Nor Laegeforen. Transdermal therapeutic

systems for drug administration 2009;12:532-3.

Gordon MN, Muller CD, Sherman KA, Morgan DG, Azzaro AJ, Wecker L.

Oral versus transdermal selegiline: Antidepressant-like activity in rats.

Pharmacol Biochem Behav 1999;63:501-6.

Miyazaki T, Hanaoka K, Namiki A, Ogawa S, Kitajima T, Hosokawa T,

et al. Efficacy, safety and pharmacokinetic study of a novel fentanyl-

containing matrix transdermal patch system in Japanese patients with

cancer pain. Clin Drug Investig 2008;28:313-25.

Graziottin A. A review of transdermal hormonal contraception: Focus

on the ethinylestradiol/norelgestromin contraceptive patch. Treat

Endocrinol 2006;5:359-65.

Berner B, John VA. Pharmacokinetic characterisation of transdermal

delivery systems. Clin Pharmacokinet 1994;26:121-34.

Chandrashekar NS, Shobha Rani RH. Physicochemical and

pharmacokinetic parameters in drug selection and loading for

transdermal drug delivery. Indian J Pharma Sci 2008;70:94-6.

Manna A, Ghosh I, Sen N, Thakur RS, Ghosh LK, Gupta BK. Statistical

optimization of transdermal drug delivery system of terbutaline sulfate

by factorial analysis. Boll Chim Farm 2000;139:34-40.

Benson HA. Transdermal drug delivery: Penetration enhancement

techniques. Curr Drug Deliv. 2005;2:23-33.

Cross SE, Robert S. Targeting local tissues by transdermal application:

Understanding drug physicochemical properties that best exploit

protein binding and blood flow effects. Drug Dev Res 1999;46:309-15.

Williams AC, Barry BW. Skin absorption enhancers. Crit Rev Ther Drug

Carrier Syst 1992;9:305-53.

Carmichael AJ, Foulds IS. Allergic contact dermatitis from transdermal

nitroglycerin. Contact Dermatitis 1989;21:113-4.

Wolf R, Tüzün B, Tüzün Y. Adverse skin reactions to the nicotine

transdermal system. Clin Dermatol. 1998;16:617-23.

Roche Gamón E, de la Cuadra Oyanguren J, Pérez Ferriols A, Fortea

Baixauli JM. Contact dermatitis from nitroglycerin in a transdermal

therapeutic system. Acta Derm Venereol 2006;86:544-5.

Kounis NG, Zavras GM, Papadaki PJ, Soufras GD, Poulos EA,

Goudevenos J, et al. Allergic reactions to local glyceryl trinitrate

administration. Br J Clin Pract 1996;50:437-9.

Zurawin RK, Ayensu-Coker L. Innovations in contraception: A review.

Clin Obstet Gynecol 2007;50:425-39.



  • There are currently no refbacks.